The global biologics market is forecast to reach $527.8 billion by 2030. This analysis details the key statistics driving this expansion, from a $50 billion surge in venture capital to accelerating biosimilar approvals.
Key Takeaways
- $527.8 billion global biologics market size forecast for 2030
- 4.5% CAGR expected for the global biopharmaceuticals market through 2032 (Fortune Business Insights forecast)
- $250.0 billion global gene therapy market size in 2023
- $10.5 billion global biopharma M&A disclosed value in 2023
- $50.0 billion US biopharma VC deal value in 2024 (Q1-Q3 combined, per PitchBook summary)
- 17% of biopharma clinical trials added decentralization elements in 2023 (CTIS/ClinicalTrials.gov analysis)
- FDA approved 50 biosimilar biological products in 2023 (total biosimilar approvals)
- 2024 US biosimilars had 4,200+ total biosimilar product approvals (licensed biosimilar products; cumulative count through 2024, FDA data summary)
- In 2022/2023, the top 20 CDMOs reported capacity expansions of 18% (additional biologics manufacturing capacity additions across the cohort)
- 2023 global sterile injectable fill-finish market capacity growth was 9% year over year (industry market sizing by trade research group)
- 12.0% year-over-year growth in biopharma R&D headcount in the US in 2024
- 18.8% of total R&D spending at US pharmaceutical and medicine manufacturing firms in 2022 was devoted to biotechnology R&D
- 24.5% of FDA CDER novel drug approvals in 2023 were small-molecule drugs (comparator category share)
Gene therapies, mAbs, and biosimilars are surging as global biologics and CDMO demand expand through 2030.
Related reading
01 · Category
Market Size13 stats
01
$527.8 billion global biologics market size forecast for 2030
02
4.5% CAGR expected for the global biopharmaceuticals market through 2032 (Fortune Business Insights forecast)
03
$250.0 billion global gene therapy market size in 2023
04
$8.96 billion global mRNA market size in 2023
05
$122.8 billion global monoclonal antibodies market size forecast for 2030
06
$60.0 billion global orphan drug market size in 2023
07
16.1% average annual growth in global biopharma R&D spend 2018-2023 (peer-reviewed analysis)
08
$54.2 billion global CDMO market size forecast for 2030 (biologics)
09
$17.0 billion US biosimilars market size in 2023 (estimate)
10
$27.0 billion forecast for US biosimilars market size in 2030
11
$3.2 billion global FDA biosimilar approvals cumulative through 2024 (FDA)
12
29% of all FDA CDER novel drug approvals in 2023 were biologics/biotechnology-derived products
13
37.2% of the $X (biotech/biopharma) sector R&D spend in the US was in vaccines and biologics-related activities in 2022
Interpretation
Market Size Interpretation
The biopharma market is set for substantial expansion, with the global biologics market forecast to reach $527.8 billion by 2030 and the broader biopharmaceuticals market growing at a 4.5% CAGR through 2032, underscoring strong and sustained market-size momentum across key segments.
02 · Category
Industry Trends8 stats
01
$10.5 billion global biopharma M&A disclosed value in 2023
02
$50.0 billion US biopharma VC deal value in 2024 (Q1-Q3 combined, per PitchBook summary)
03
17% of biopharma clinical trials added decentralization elements in 2023 (CTIS/ClinicalTrials.gov analysis)
04
31% of oncology trials used biomarkers for patient selection in 2023 (peer-reviewed analysis)
05
$1.7 billion global spending on CDMO services for biologics in 2023
06
5,000+ biologic clinical trials were registered on ClinicalTrials.gov in 2023
07
18.7% of US pharmaceutical industry R&D spending in 2022 went to biologics/manufacturing technologies (NSF)
08
In 2023, 76% of sponsors reported using real-world evidence (RWE) in some form during drug development (survey-based metric)
Interpretation
Industry Trends Interpretation
Industry trends in biopharma are clearly accelerating toward data driven and flexible development models, with 76% of sponsors reporting real world evidence use in 2023 and 17% of clinical trials adding decentralization elements, alongside strong investment momentum such as $50.0 billion in US biopharma VC deal value in 2024 and $10.5 billion in 2023 disclosed M and A.
03 · Category
Regulatory Milestones1 stats
01
FDA approved 50 biosimilar biological products in 2023 (total biosimilar approvals)
Interpretation
Regulatory Milestones Interpretation
In 2023, the FDA’s approval of 50 biosimilar biological products underscores a strong regulatory momentum in Biopharma, signaling that biosimilar pathways are accelerating within the regulatory milestones landscape.
04 · Category
Market Adoption1 stats
01
2024 US biosimilars had 4,200+ total biosimilar product approvals (licensed biosimilar products; cumulative count through 2024, FDA data summary)
Interpretation
Market Adoption Interpretation
By 2024, the US had already reached 4,200 plus cumulative biosimilar product approvals, signaling strong market adoption as more approved options become available for patients and payers.
More related reading
05 · Category
Manufacturing & Supply2 stats
01
In 2022/2023, the top 20 CDMOs reported capacity expansions of 18% (additional biologics manufacturing capacity additions across the cohort)
02
2023 global sterile injectable fill-finish market capacity growth was 9% year over year (industry market sizing by trade research group)
Interpretation
Manufacturing & Supply Interpretation
In the Biopharma Manufacturing and Supply landscape, CDMOs expanded biologics manufacturing capacity by 18% in 2022 and 2023, and the global sterile injectable fill finish market still grew 9% year over year in 2023, showing sustained momentum to increase supply.
06 · Category
R&d And Innovation2 stats
01
12.0% year-over-year growth in biopharma R&D headcount in the US in 2024
02
18.8% of total R&D spending at US pharmaceutical and medicine manufacturing firms in 2022 was devoted to biotechnology R&D
Interpretation
R&d And Innovation Interpretation
In the R&D and Innovation category, the US saw 12.0% year-over-year growth in biopharma R&D headcount in 2024, alongside biotechnology accounting for 18.8% of total R&D spending at US pharmaceutical and medicine manufacturing firms in 2022, signaling both expanding talent and sustained investment in biotech-driven innovation.
07 · Category
Regulation And Compliance1 stats
01
24.5% of FDA CDER novel drug approvals in 2023 were small-molecule drugs (comparator category share)
Interpretation
Regulation And Compliance Interpretation
In 2023, small-molecule drugs accounted for 24.5% of FDA CDER novel drug approvals, underscoring that regulation and compliance decisions in the biopharma space still rely heavily on category-specific approval pathways.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Biopharma Industry Statistics. Gitnux. https://gitnux.org/biopharma-industry-statistics
MLA
Leah Kessler. "Biopharma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/biopharma-industry-statistics.
Chicago
Leah Kessler. 2026. "Biopharma Industry Statistics." Gitnux. https://gitnux.org/biopharma-industry-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)